M. Pappagallo
Papers
1
Total Citations
6
H-Index
1
About
Dr. M. Pappagallo is a pioneering researcher in pain medicine and psychiatric pharmacotherapy, with a focus on novel treatments for treatment-resistant depression and dissociative disorders. His most notable contribution involves investigating REL-1017 (esmethadone), a novel N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting intervention for dissociative symptoms in major depressive disorder unresponsive to standard antidepressants. This work, published in 2022, addresses a critical gap in psychiatric care, as dissociative disorders are highly prevalent yet frequently underdiagnosed—affecting up to 29% of psychiatric outpatients, with only 5% previously identified. While his research is still accumulating citations, its clinical relevance is significant, offering hope for patients with limited treatment options. Dr. Pappagallo’s expertise bridges neurology and psychiatry, emphasizing the translational potential of glutamatergic modulation. His ongoing studies continue to shape understanding of how esmethadone may rapidly reduce dissociative states, marking him as a key figure in advancing personalized, mechanism-based therapies for complex mood disorders.
Research Focus
Key Achievements
Top Papers
- 1